GASTROINTESTINAL ABNORMALITIES AND INVOLVEMENT IN SYSTEMIC MASTOCYTOSIS

https://doi.org/10.1016/S0889-8588(05)70298-7Get rights and content

Section snippets

HISTORY OF GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC MASTOCYTOSIS

In 1869, Nettleship and Tay159 described a 2-year-old child with hyperpigmented, urticarial skin lesions. Their report is credited as being the first description of urticaria pigmentosa. It was not until 187754 that mast cells were first described by Ehrlich, who found cells possessing cytoplasmic granules that stained metachromatically with aniline dyes. He called these cells “mastzellen” because they were distended with granules. Subsequently, in 1878, Sangster191 described a patient with a

FREQUENCY OF GASTROINTESTINAL SYMPTOMS IN SYSTEMIC MASTOCYTOSIS

As Table 1 shows, the reported frequency of occurrence of gastrointestinal symptoms in patients with systemic mastocytosis has varied greatly in different series.* In the 16 series in Table 1, the mean is 51%, with a range from 14% to 85%. In the early large reviews performed before 1963 by Demis et al49, 50, 51 involving 221, 90, and 113 patients, respectively, only 14% to 24% of all patients had

GASTROINTESTINAL SYMPTOMS AND SIGNS IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS

As Table 2 shows, the frequency of various gastrointestinal symptoms reported in 13 different series* in patients with systemic mastocytosis is less variable than their prevalence (compare with Table 2 and Table 1). In 11 of the 13 series where data were available, abdominal pain was the most common gastrointestinal symptom, occurring with an average frequency of 51% and with a range from 12% to 100% in different

GASTROINTESTINAL ABNORMALITIES AND INVOLVEMENT IN SYSTEMIC MASTOCYTOSIS

Structural and functional gastrointestinal abnormalities reported in systemic mastocytosis are summarized by frequency of signs in Table 2 and by organ involvement inBox 1. These abnormalities are discussed here and in the next section dealing with the pathogenesis of various symptoms and signs in systemic mastocytosis.

Gastrointestinal Involvement or Abnormalities Reported in Patients with Systemic Mastocytosis

  • Esophageal

    • Esophagitis

    • Esophageal stricture (secondary

PATHOGENESIS OF GASTROINTESTINAL SYMPTOMS AND SIGNS IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS

The gastrointestinal symptoms and signs associated with systemic mastocytosis listed in Table 1. In most cases discussed here, the exact pathogenesis remains unclear. This uncertainty arises in large part because the rarity of systemic mastocytosis makes a rigorous study of a large number of patients difficult. Furthermore, the protean manifestations of systemic mastocytosis combined with the four different categories of the disease make generalizations difficult and increase the difficulty of

DIFFERENTIAL DIAGNOSIS OF SYSTEMIC MASTOCYTOSIS IN COMPARISON WITH OTHER GASTROINTESTINAL DISEASES

In most patients with systemic mastocytosis the principal clinical manifestations include a cutaneous rash (urticaria pigmentosa) with or without flushing episodes combined with abdominal pain (dyspeptic and nondyspeptic), diarrhea, and, occasionally, malabsorption (see Table 2). Some patients with well-documented systemic mastocytosis, especially those with category II to category IV disease, present without urticaria pigmentosa †

TREATMENT

Treatment of systemic mastocytosis has been covered in a number of reviews.41, 75, 81, 147, 148, 215 Therefore, it is discussed only briefly here to emphasize some important points related to gastrointestinal symptoms.

The goal of treatment of systemic mastocytosis is twofold. The first goal is to control the effects of the overproduction of mast cell mediators which result primarily in flushing, pruritus, anaphylaxis, and gastrointestinal symptoms (abdominal pain, diarrhea, nausea, vomiting).

SUMMARY

Recent studies have shown that involvement of the gastrointestinal tract is much more frequent than originally reported in patients with systemic mastocytosis. Seventy percent to 80% of patients with systemic mastocytosis are found to have gastrointestinal symptoms when a careful history is taken, and abnormalities in the gastrointestinal tract are frequently detected by endoscopic studies, functional studies of absorption, and barium studies. Because of the rarity of the disease, there are few

First page preview

First page preview
Click to open first page preview

References (238)

  • B.M. Czarnetzki et al.

    Interferon treatment of patients with chronic urticaria and mastocytosis

    J Am Acad Dermatol

    (1994)
  • S.D. Freedman et al.

    Recurrent gastrointestinal bleeding associated with myelofibrosis and diffuse intestinal telangiectasias

    Gastroenterology

    (1991)
  • B.S. Friedman et al.

    Analysis of plasma histamine levels in patients with mast cell disorders

    Am J Med

    (1989)
  • M. Frieri et al.

    Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial

    Am J Med

    (1985)
  • J.W. Gerrard et al.

    Urticaria pigmentosa: Treatment with cimetidine and chlorpheniramine

    J Pediatr

    (1979)
  • L. Golkar et al.

    Mastocytosis

    Lancet

    (1997)
  • G. Granerus et al.

    Studies on histamine metabolism

    J Invest Dermatol

    (1983)
  • T.K. Gray et al.

    Ion transport changes during calcitonin-induced intestinal secretion in man

    Gastroenterology

    (1976)
  • R.S. Gruchalla

    Southwestern internal medicine conference: Mastocytosis: Developments during the past decade

    Am J Med Sci

    (1995)
  • S. Grundfest et al.

    Portal hypertension associated with systemic mastocytosis and splenomegaly

    Gastroenterology

    (1980)
  • R.F. Horan et al.

    Cromolyn sodium in the management of systemic mastocytosis

    J Allergy Clin Immunol

    (1990)
  • S.W. Hutton et al.

    Thyrotropin-releasing hormone suppresses gastric acid output in patients with Zollinger-Ellison syndrome and systemic mastocytosis

    Am J Med

    (1981)
  • S.N. Adler et al.

    Bleeding after liver biopsy in a patient with systemic mastocytosis and malabsorption

    J Clin Gastroenterol

    (1985)
  • R.R. Alexander

    Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone

    Acta Haematol

    (1985)
  • R. Ammann et al.

    Malabsorption syndrome in generalized mastocytosis [German]

    Schweiz Med Wochenschr

    (1972)
  • R.W. Ammann et al.

    Gastrointestinal involvement in systemic mastocytosis

    Gut

    (1967)
  • Anonymous

    Systemic mastocytosis

    Am J Med

    (1976)
  • B.J. Bain

    Systemic mastocytosis and other mast cell neoplasms

    Br J Haematol

    (1999)
  • S. Bank et al.

    Malabsorption in systemic mast cell disease

    Gastroenterology

    (1963)
  • L.A. Barker et al.

    Histamine H2-receptors on guinea-pig ileum myenteric plexus neurons mediate the release of contractile agents

    J Pharmacol Exp Ther

    (1982)
  • H. Barriere et al.

    Mastocytose systemique et malabsorption intestinale

    Semaine des Hopitaux Paris

    (1983)
  • W. Bartelheimer et al.

    Mastocytosis in the intestinal tract

    Z Gastroenterol

    (1974)
  • M.C. Belcon et al.

    Gastrointestinal hemorrhage in mastocytosis

    CMAJ

    (1980)
  • M.J. Berg et al.

    Cimetidine in systemic mastocytosis

    Drug Intelligence Clinical Pharmacy

    (1981)
  • M. Berke et al.

    Generalized mastocytosis. Fatal case with autopsy findings

    California Medicine

    (1967)
  • C. Berlin

    Urticaria pigmentosa as a systemic disease

    Arch Dermatol

    (1955)
  • G. Bloom et al.

    Malignant systemic mast cell disease (mastocytoma) in man

    Acta Medica Scandinavica

    (1960)
  • P. Bonnet et al.

    Intractable ascites in systemic mastocytosis treated by portal diversion

    Dig Dis Sci

    (1987)
  • F. Borda et al.

    Gastroscopic findings in systemic mastocytosis

    Endoscopy

    (1983)
  • C. Bordi et al.

    Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I

    Am J Surg Pathol

    (1997)
  • D.Z. Braverman et al.

    Clinical, histological, and electron microscopic study of mast cell disease of the small bowel

    Am J Gastroenterol

    (1985)
  • J.E. Bredfeldt et al.

    Malabsorption and gastric hyperacidity in systemic mastocytosis

    Am J Gastroenterol

    (1980)
  • R.D. Brunning et al.

    Systemic mastocytosis: Extracutaneous manifestations

    Am J Surg Pathol

    (1993)
  • BurklowS.L. et al.

    Mastocytosis: One year's experience

    South Med J

    (1987)
  • J.H. Butterfield

    Response of severe systemic mastocytosis to interferon alpha

    Br J Dermatol

    (1998)
  • Y. Calmus et al.

    Ascites inaugurating systemic mastocytosis

    Ann Med Interne (Paris)

    (1981)
  • W.I. Card et al.

    The relationship between the acid output of the stomach following “maximal” histamine stimulation and the parietal cell mass

    Clin Sci (London)

    (1960)
  • A.H. Christensen et al.

    Duodenal ulcer in systemic mastocytosis

    Ugeskrift fur Laeger (Copenhagen)

    (1991)
  • A.R. Clemett et al.

    Gastrointestinal lesions in mastocytosis

    American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine

    (1968)
  • C.F. Code

    Histamine and gastric secretion: A later look, 1955–1965

    Federation Proceedings

    (1965)
  • Cited by (139)

    View all citing articles on Scopus

    Address reprint requests to Robert T. Jensen, MD, NIH/NIDDK/DDB, Building 10, Room 9C-103, 10 Center Drive MSC 1804, Bethesda, MD 20892–1804

    *

    Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

    View full text